Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Haematologica

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    August 2017
  1. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Text format     Abstract available


    July 2017
  2. MONDELAERS V, Suciu S, De Moerloose B, Ferster A, et al
    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Haematologica. 2017 Jul 27. pii: haematol.2017.165845.
    PubMed     Text format     Abstract available


  3. JALLADES L, Baseggio L, Sujobert P, Huet S, et al
    Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
    Haematologica. 2017 Jul 27. pii: haematol.2016.160192.
    PubMed     Text format     Abstract available


  4. JAIS JP, Molina TJ, Ruminy P, Gentien D, et al
    Reliable subtype classification of diffuse large B-Cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
    Haematologica. 2017 Jul 4. pii: haematol.2017.166827.
    PubMed     Text format    


  5. FERRERO S, Dreyling M
    Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
    Haematologica. 2017;102:1133-1136.
    PubMed     Text format    


    June 2017
  6. VAN DE KROGT JA, Vanden Bempt M, Finalet Ferreiro J, Mentens N, et al
    ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    Haematologica. 2017 Jun 28. pii: haematol.2016.146571.
    PubMed     Text format     Abstract available


  7. EHRENTRAUT S, Nagel S, Pommerenke C, Dirks WG, et al
    Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).
    Haematologica. 2017 Jun 28. pii: haematol.2017.168203.
    PubMed     Text format    


  8. BRON D, Aurer I, Andre MPE, Bonnet C, et al
    Unmet needs in the scientific approach to older patients with lymphoma.
    Haematologica. 2017;102:972-975.
    PubMed     Text format    


    May 2017
  9. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed     Text format    


    April 2017
  10. STEVENS WBC, Mendeville M, Redd R, Clear AJ, et al
    Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium.
    Haematologica. 2017 Apr 14. pii: haematol.2017.165415.
    PubMed     Text format     Abstract available


  11. NOBLE RA, Bell N, Blair H, Sikka A, et al
    Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Haematologica. 2017 Apr 6. pii: haematol.2016.163030.
    PubMed     Text format     Abstract available


  12. BI C, Zhang X, Lu T, Zhang X, et al
    Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.
    Haematologica. 2017;102:755-764.
    PubMed     Text format     Abstract available


    March 2017
  13. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation.
    Haematologica. 2017 Mar 24. pii: haematol.2017.164996.
    PubMed     Text format     Abstract available


  14. DENG AL, Kim YR, Lichtenstein EA, O'Connor OA, et al
    Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B cell lymphoma leg type with mutant MYD88 and wildtype CD79.
    Haematologica. 2017 Mar 24. pii: haematol.2016.161893.
    PubMed     Text format    


  15. WEBERPALS J, Pulte D, Jansen L, Luttmann S, et al
    Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States in the early 21st century.
    Haematologica. 2017 Mar 9. pii: haematol.2016.157768.
    PubMed     Text format    


    February 2017
  16. ROHDE M, Bonn BR, Zimmermann M, Lange J, et al
    Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols.
    Haematologica. 2017 Feb 16. pii: haematol.2016.156885.
    PubMed     Text format     Abstract available


  17. MERIRANTA L, Pasanen A, Louhimo R, Cervera A, et al
    Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.
    Haematologica. 2017 Feb 9. pii: haematol.2016.157495.
    PubMed     Text format    


  18. VERHOEF G, Robak T, Huang H, Pylypenko H, et al
    Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase III LYM-3002 study.
    Haematologica. 2017 Feb 9. pii: haematol.2016.152496.
    PubMed     Text format     Abstract available


  19. BASHASH M, Connors JM, Gascoyne RD, Meissner B, et al
    Genetic Polymorphism at BCL2 as a predictor for R-CHOP efficacy in patients with diffuse large B-cell lymphoma.
    Haematologica. 2017 Feb 2. pii: haematol.2016.159087.
    PubMed     Text format    


  20. HERTZBERG M, Gandhi MK, Trotman J, Butcher B, et al
    Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Haematologica. 2017;102:356-363.
    PubMed     Text format     Abstract available


    January 2017
  21. RIBRAG V, Kim WS, Bouabdallah R, Lim ST, et al
    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study.
    Haematologica. 2017 Jan 25. pii: haematol.2016.154377.
    PubMed     Text format     Abstract available


  22. DOBAY MP, Lemonnier F, Missiaglia E, Bastard C, et al
    Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.
    Haematologica. 2017 Jan 12. pii: haematol.2016.158428.
    PubMed     Text format    


  23. ZAJA F, Ferrero S, Stelitano C, Ferrari A, et al
    Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi.
    Haematologica. 2017 Jan 12. pii: haematol.2016.154211.
    PubMed     Text format    


    December 2016
  24. GRIGG A, Dyer MJ, Gonzalez Diaz M, Dreyling M, et al
    Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Haematologica. 2016 Dec 23. pii: haematol.2016.152272.
    PubMed     Text format     Abstract available


  25. SALLES G, Schuster SJ, de Vos S, Wagner-Johnston ND, et al
    Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
    Haematologica. 2016 Dec 15. pii: haematol.2016.151738.
    PubMed     Text format    


  26. LE GUYADER-PEYROU S, Orazio S, Dejardin O, Maynadie M, et al
    Factors related to diffuse large B-cell lymphoma relative survival in a population-based study in France: is there a role of socio-economic status?
    Haematologica. 2016 Dec 1. pii: haematol.2016.152918.
    PubMed     Text format     Abstract available


  27. VAN KEIMPEMA M, Gruneberg LJ, Schilder-Tol EJ, Oud ME, et al
    The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    Haematologica. 2016 Dec 1. pii: haematol.2016.156455.
    PubMed     Text format     Abstract available


    November 2016
  28. HUDE I, Sasse S, Engert A, Brockelmann PJ, et al
    The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Haematologica. 2016 Nov 24. pii: haematol.2016.150656.
    PubMed     Text format     Abstract available


  29. ZIJLSTRA JM, Burggraaff CN, Kersten MJ, Barrington SF, et al
    FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
    Haematologica. 2016;101:1279-1283.
    PubMed     Text format    


    October 2016
  30. PENALVER FJ, Sancho JM, de la Fuente A, Olave MT, et al
    Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
    Haematologica. 2016 Oct 20. pii: haematol.2016.149120.
    PubMed     Text format     Abstract available


  31. MATHUR R, Sehgal L, Havranek O, Kohrer S, et al
    Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
    Haematologica. 2016 Oct 14. pii: haematol.2016.144964.
    PubMed     Text format     Abstract available


  32. SARKOZY C, Molina T, Ghesquieres H, Michallet AS, et al
    Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA.
    Haematologica. 2016 Oct 6. pii: haematol.2016.152256.
    PubMed     Text format     Abstract available


    September 2016
  33. FICHTNER M, Spies E, Seismann H, Riecken K, et al
    Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.
    Haematologica. 2016;101:e378-81.
    PubMed     Text format    


  34. ROSENQUIST R, Rosenwald A, Du MQ, Gaidano G, et al
    Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.
    Haematologica. 2016;101:1002-9.
    PubMed     Text format     Abstract available


    August 2016
  35. ATTARBASCHI A, Carraro E, Abla O, Barzilai-Birenboim S, et al
    Non-Hodgkin's lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.
    Haematologica. 2016 Aug 11. pii: haematol.2016.147116.
    PubMed     Text format     Abstract available


    July 2016
  36. ZINZANI PL, Karlin L, Radford J, Caballero D, et al
    European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
    Haematologica. 2016 Jul 14. pii: haematol.2016.146977.
    PubMed     Text format    


  37. KUMAR A, Burger IA, Zhang Z, Drill EN, et al
    Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.
    Haematologica. 2016 Jul 6. pii: haematol.2016.141846.
    PubMed     Text format     Abstract available


  38. ROTUNNO M, McMaster ML, Boland J, Bass S, et al
    Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene.
    Haematologica. 2016;101:853-60.
    PubMed     Text format     Abstract available


  39. VARDHANA S, Younes A
    The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
    Haematologica. 2016;101:794-802.
    PubMed     Text format     Abstract available


    June 2016
  40. PERRY AM, Diebold J, Nathwani BN, MacLennan KA, et al
    Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.
    Haematologica. 2016 Jun 27. pii: haematol.2016.148809.
    PubMed     Text format     Abstract available


  41. CAMUS V, Stamatoullas A, Mareschal S, Viailly PJ, et al
    Detection and prognostic value of recurrent XPO1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin Lymphoma.
    Haematologica. 2016 Jun 13. pii: haematol.2016.145102.
    PubMed     Text format     Abstract available


  42. YOO HY, Kim P, Kim WS, Lee SH, et al
    Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
    Haematologica. 2016;101:e271.
    PubMed     Text format    


  43. GONG Q, Wang C, Rohr J, Feldman AL, et al
    Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
    Haematologica. 2016;101:e269-70.
    PubMed     Text format    


    May 2016
  44. ZINZANI P, Pellegrini C, Argnani L, Broccoli A, et al
    Prolonged disease free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
    Haematologica. 2016 May 31. pii: haematol.2016.147256.
    PubMed     Text format    


  45. BLOMBERY P, Thompson E, Jones K, Mir Arnau G, et al
    Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast-implant associated anaplastic large cell lymphoma.
    Haematologica. 2016 May 19. pii: haematol.2016.146118.
    PubMed     Text format    


  46. LAURENT C, Fabiani B, Do C, Tchernonog E, et al
    Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
    Haematologica. 2016 May 12. pii: haematol.2016.141978.
    PubMed     Text format     Abstract available


  47. BATLEVI CL, Kasamon Y, Bociek RG, Lee P, et al
    ENGAGE- 501: Phase 2 study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
    Haematologica. 2016 May 5. pii: haematol.2016.142406.
    PubMed     Text format     Abstract available


    April 2016
  48. KLEINSTERN G, Abu Seir R, Perlman R, Abdeen Z, et al
    Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to Hepatitis B.
    Haematologica. 2016 Apr 21. pii: haematol.2016.144840.
    PubMed     Text format    


  49. HORIGUCHI H, Kobune M, Kikuchi S, Yoshida M, et al
    Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
    Haematologica. 2016;101:437-47.
    PubMed     Text format     Abstract available


  50. PERROT A, Monjanel H, Bouabdallah R, Quittet P, et al
    Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Haematologica. 2016;101:466-73.
    PubMed     Text format     Abstract available


    March 2016
  51. SZCZEPANOWSKI M, Masque-Soler N, Schlesner M, Haake A, et al
    Immunohistochemical detection of Inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma.
    Haematologica. 2016 Mar 18. pii: haematol.2015.138701.
    PubMed     Text format    


  52. LAMARQUE M, Bossard C, Contejean A, Brice P, et al
    Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
    Haematologica. 2016;101:e103-6.
    PubMed     Text format    


  53. DRIESSEN C, Kraus M, Joerger M, Rosing H, et al
    Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Haematologica. 2016;101:346-55.
    PubMed     Text format     Abstract available


    February 2016
  54. SACCHI S, Marcheselli R, Bari A, Buda G, et al
    Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
    Haematologica. 2016 Feb 8. pii: haematol.2015.139329.
    PubMed     Text format     Abstract available


  55. DREYLING M, Ferrero S
    The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
    Haematologica. 2016;101:104-14.
    PubMed     Text format     Abstract available


  56. FUERST D, Mueller C, Beelen DW, Neuchel C, et al
    Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
    Haematologica. 2016;101:241-7.
    PubMed     Text format     Abstract available


    January 2016
  57. YOO HY, Kim P, Kim WS, Lee SH, et al
    Frequent CTLA4-CD28 gene fusion in diverse types of T cell lymphoma.
    Haematologica. 2016 Jan 27. pii: haematol.2015.139253.
    PubMed     Text format     Abstract available


    December 2015
  58. SIBON D, Morschhauser F, Resche-Rigon M, Ghez D, et al
    Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA / SFGM-TC study group.
    Haematologica. 2015 Dec 31. pii: haematol.2015.136408.
    PubMed     Text format     Abstract available


  59. FEDERICO M, Luminari S, Pellegrini C, Merli F, et al
    Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.
    Haematologica. 2015 Dec 24. pii: haematol.2015.138388.
    PubMed     Text format    


  60. CHEMINANT M, Derrieux C, Touzart A, Schmit S, et al
    Minimal Residual Disease monitoring by 8-color flow cytometry in Mantle Cell Lymphoma: an EU-MCL and LYSA study.
    Haematologica. 2015 Dec 24. pii: haematol.2015.134957.
    PubMed     Text format     Abstract available


  61. CARTRON G, Hourcade-Potelleret F, Morschhauser F, Salles G, et al
    Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
    Haematologica. 2015 Dec 11. pii: haematol.2015.133421.
    PubMed     Text format     Abstract available


  62. NANNYA Y, Goto N, Shimizu M, Seishima M, et al
    Efficacy of rituximab maintenance therapy for aggressive B-cell lymphoma depends on use of rituximab in induction therapy: a meta-analysis of randomized controlled trials.
    Haematologica. 2015;100:e519-20.
    PubMed     Text format    


    November 2015
  63. RULE S, Smith P, Johnson PW, Bolam S, et al
    The addition of Rituximab to Fludarabine and Cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute tr
    Haematologica. 2015 Nov 26. pii: haematol.2015.128710.
    PubMed     Text format     Abstract available


  64. QIN H, Wu Q, Cowell JK, Ren M, et al
    FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.
    Haematologica. 2015 Nov 20. pii: haematol.2015.137695.
    PubMed     Text format    


    August 2015
  65. LEFEVRE G, Copin MC, Roumier C, Aubert H, et al
    CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.
    Haematologica. 2015;100:1086-95.
    PubMed     Text format     Abstract available


    July 2015
  66. FERREIRO JF, Morscio J, Dierickx D, Marcelis L, et al
    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.
    Haematologica. 2015;100:e275-9.
    PubMed     Text format    


    June 2015
  67. DING J, Dirks WG, Ehrentraut S, Geffers R, et al
    BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Haematologica. 2015;100:801-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: